Search Result

Results for "

Xa

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor Xa (99) Autophagy (2) Bacterial (3) Biochemical Assay Reagents (5) Cathepsin (1) CD20 (1) COX (1) Cytochrome P450 (1) Drug Metabolite (3) Endogenous Metabolite (3) ERK (1) Exosomes (1) Factor VIIa (2) Flavivirus (1) Fluorescent Dye (1) FXR (1) Influenza Virus (1) Isotope-Labeled Compounds (6) JNK (1) Kallikrein (3) MMP (2) Proteasome (2) Reference Standards (9) SARS-CoV (3) Ser/Thr Protease (12) Thrombin (32) Tissue Factor Pathway Inhibitor (TFPI) (2) TMPRSS6 (1) VEGFR (2)
By Research Areas:	Cancer (20) Cardiovascular Disease (99) Infection (7) Inflammation/Immunology (8) Metabolic Disease (4) Neurological Disease (1)
Oligonucleotides:	Aptamers (2)

129

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Factor Xa

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17567A

Heparin sodium salt Maximum Cited Publications 59 Publications Verification Sodium heparin; Sodium heparinate	Exosomes Thrombin Factor Xa Autophagy	Cardiovascular Disease Cancer
Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.

HY-50667

Apixaban 10+ Cited Publications BMS-562247-01	Factor Xa	Cardiovascular Disease Cancer
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-50903

Rivaroxaban 15+ Cited Publications BAY 59-7939	Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-17567C

Heparin sodium salt (MW 15kDa) 3 Publications Verification Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)	Thrombin Factor Xa Autophagy	Cardiovascular Disease
Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa .

HY-10264

Edoxaban 5+ Cited Publications DU-176	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-10268

Betrixaban 5 Publications Verification PRT054021	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-B0385

Gabexate mesylate 4 Publications Verification FOY	Proteasome Factor Xa	Inflammation/Immunology
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with K_is of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with K_is of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

HY-B0597

Fondaparinux sodium 4 Publications Verification Fondaparin sodium; SR-90107A	Factor Xa	Cardiovascular Disease Cancer
Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

HY-10264B

Edoxaban tosylate monohydrate 5+ Cited Publications DU-176b monohydrate	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-10264A

Edoxaban tosylate 5+ Cited Publications DU-176b	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .

HY-119124

Edoxaban M4 D21-2393	Factor Xa	Cardiovascular Disease Inflammation/Immunology
Edoxaban M4 (D21-2393) is an orally active and selective Factor Xa inhibitor with a human Factor Xa IC₅₀ of 1.8 nM. Edoxaban M4 exhibits anticoagulant activity via Factor Xa inhibition. Edoxaban M4 can be used for the research of non-valvular atrial fibrillation, venous thromboembolisms, pulmonary embolism .

HY-P990060

Denecimig Mim8	Factor Xa	Cardiovascular Disease
Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A .

HY-50903S

Rivaroxaban-d4 1 Publications Verification BAY 59-7939-d₄	Factor Xa	Cardiovascular Disease
Rivaroxaban-d₄ (BAY 59-7939-d₄) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-50667S

Apixaban-13C,d3 BMS-562247-01-¹³C,d₃	Factor Xa	Cardiovascular Disease
Apixaban- ¹³C,d₃ (BMS-562247-01- ¹³C,d₃) is a deuterium and ¹³C labeled Apixaban (HY-50667). Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-N6987

Licraside	FXR Factor Xa	Cardiovascular Disease Inflammation/Immunology
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-P99326

Tositumomab Anti-Human CD20 Recombinant Antibody; V10Xa53	CD20	Cancer
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .

HY-153829

CH3OCO-D-CHA-Gly-Arg-pNA acetate	Factor Xa	Cardiovascular Disease
CH3OCO-D-CHA-Gly-Arg-pNA acetate is a chromogenic substrate for factor Xa .

HY-P3009

Bovine Factor Xa	Factor Xa	Cardiovascular Disease
Bovine Factor Xa, a trypsin-like serine protease, is an important player in the coagulation cascade responsible for thrombin generation .

HY-100655

O-Desmethyl apixaban	Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-18660

Ciraparantag PER977	Factor Xa Thrombin	Cardiovascular Disease
Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

HY-50667R

Apixaban (Standard) BMS-562247-01 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease Cancer
Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-10268A

Betrixaban maleate 5 Publications Verification PRT054021 maleate	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) maleate is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban maleate shows antithrombotic effect .

HY-75680

Apixaban ethyl ester	Factor Xa	Cardiovascular Disease
Apixaban ethyl ester is a key intermediate in the synthesis of FXa inhibitors, which is used to study the inhibitory activity against venous thrombosis .

HY-76948

5-R-Rivaroxaban 1 Publications Verification	Factor Xa	Cardiovascular Disease
5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM).

HY-50903R

Rivaroxaban (Standard) BAY 59-7939 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease Cancer
Rivaroxaban (Standard) is the analytical standard of Rivaroxaban. This product is intended for research and analytical applications. Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-50667S1

Apixaban-d3 BMS-562247-01-d₃	Isotope-Labeled Compounds Factor Xa	Others
Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_is of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-P3126

Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride	Factor Xa	Others
Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate .

HY-134685

Edoxaban impurity 6	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban impurity 6 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K_is of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .

HY-134686

Edoxaban impurity 4	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K_is of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention .

HY-10724

Fidexaban ZK-807834; CI-1031	Factor Xa	Cardiovascular Disease
Fidexaban is a Factor Xa inhibitor and can be used in research of cardiovascular disease .

HY-10268S

Betrixaban-d6 PRT054021-d₆	Factor Xa	Cardiovascular Disease
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor .

HY-W854549

Heparin pentasaccharide Fondaparinux free acid	Factor Xa	Cardiovascular Disease
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .

HY-P5027

Cbz-Lys-Arg-pNA	Ser/Thr Protease Kallikrein Factor Xa Thrombin	Cardiovascular Disease
Cbz-Lys-Arg-pNA is a peptide substrate containing pNA as the chromogenic group. Cbz-Lys-Arg-pNA is widely used in enzymatic analysis, including thrombin, plasmin, factor Xa and Kallikrein .

HY-76971

Dechloro Rivaroxaban	Factor Xa	Cardiovascular Disease
Dechloro Rivaroxaban is a highly selective, orally active inhibitor of Factor Xa. Dechloro Rivaroxaban inhibits human free FXa with a K_i of 0.4 nM. Dechloro Rivaroxaban inhibits prothrombinase activity and fibrin-associated FXa activity with IC₅₀s of 2.1 nM and 92 nM, respectively .

HY-166257

Lyso-sulfatide (bovine) Psychosine 3′-O-sulfate; Psychosine 3′-sulfate	Biochemical Assay Reagents Factor Xa	Metabolic Disease
Lyso-sulfatide (bovine) is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions .

HY-10268B

Betrixaban hydrochloride PRT054021 hydrochloride	Factor Xa	Cardiovascular Disease
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect .

HY-10268R

Betrixaban (Standard) PRT054021 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease
Betrixaban (Standard) is the analytical standard of Betrixaban. This product is intended for research and analytical applications. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-14853

Darexaban YM150	Factor Xa Ser/Thr Protease	Cardiovascular Disease
Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC₅₀ of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .

HY-P3009A

Canine Factor Xa	Factor Xa	Cardiovascular Disease
Canine Factor Xa is prepared by activating purified Canine Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.

HY-P3009D

Rat Factor Xa	Factor Xa	Cardiovascular Disease
Rat Factor Xa is prepared by activating purified Rat Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.

HY-P3009C

Rabbit Factor Xa	Factor Xa	Cardiovascular Disease
Rabbit Factor Xa is prepared by activating purified Rabbit Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.

HY-P3009B

Porcine Factor Xa	Factor Xa	Cardiovascular Disease
Porcine Factor Xa is prepared by activating purified Porcine Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.

HY-12605

SAR107375	Thrombin	Metabolic Disease
SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with K_i values of 1 nM and 8 nM for factor Xa and thrombin, respectively .

HY-129973

4-Chlorophenylurea NSC-12971; 4-Chlorophenylurea	Factor Xa	Others
4-Chlorophenylurea is metabolite of diflubenzuron (HY-B1973). 4-Chlorophenylurea can be used to form factor Xa inhibitors .

HY-10782

KFA-1982	Factor Xa	Cardiovascular Disease
KFA-1982 is a potent, selective and orally active factor Xa inhibitor. KFA-1982 can be used for the research of cardiovascular disease, such as thrombosis .

HY-172316

BAY 3389934	Factor Xa	Cardiovascular Disease
BAY 3389934 is a selective dual inhibitor of factor IIa and factor Xa, with an IC₅₀ of 4.9 nM for factor IIa and an IC₅₀ of 0.66 nM for factor Xa. BAY 3389934 directly inhibits the activities of factor IIa and factor Xa and regulates the common coagulation pathway. BAY 3389934 exhibits anticoagulant and organ-protective effects. BAY 3389934 can be used in the research of sepsis and coagulopathy .

HY-10769

ZK-813039	Factor Xa	Cardiovascular Disease
ZK-813039 is a potent and orally active factor Xa inhibitor. ZK-813039 can prolong prothrombin time. ZK-813039 can be used for the research of cardiovascular disease .

HY-B0597R

Fondaparinux sodium (Standard) Fondaparin sodium (Standard); SR-90107A (Standard)	Reference Standards Factor Xa	Cardiovascular Disease Cancer
Fondaparinux (sodium) (Standard) is the analytical standard of Fondaparinux (sodium). This product is intended for research and analytical applications. Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor.

HY-153817

FXIa-IN-13	Factor Xa	Cardiovascular Disease
FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .

Cat. No.	Product Name	Target	Research Area

HY-P2185A

NFF-3 TFA	MMP	Others
NFF-3 TFA, the peptide, is a selective MMP substrate. NFF-3 TFA selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 TFA is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 TFA with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .

HY-P5107

Low molecular weight protamine LMWP; TDSP5	VEGFR	Cancer
Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, *anti-Xa* and anti-IIa activities, and also neutralizes *anti-Xa* activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds .

HY-P6023

D-Leu-Pro-Arg-Rh110-D-Pro	Factor Xa	Cardiovascular Disease
D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity .

HY-P3126

Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride	Factor Xa	Others
Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate .

HY-P5027

Cbz-Lys-Arg-pNA	Ser/Thr Protease Kallikrein Factor Xa Thrombin	Cardiovascular Disease
Cbz-Lys-Arg-pNA is a peptide substrate containing pNA as the chromogenic group. Cbz-Lys-Arg-pNA is widely used in enzymatic analysis, including thrombin, plasmin, factor Xa and Kallikrein .

HY-P2185

NFF-3	MMP	Others
NFF-3, the peptide, is a selective MMP substrate. NFF-3 selectively binds to MMP-3 and MMP-10 to be hydrolyzed. NFF-3 is also cleaved by trypsin, hepatocyte growth factor activator, and factor Xa. Label NFF-3 with a CyDye pair, Cy3/Cy5Q, can produce fluorescence in cell assays to detect cell activity .

HY-P6023A

D-Leu-Pro-Arg-Rh110-D-Pro TFA	Factor Xa	Cardiovascular Disease
D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity .

HY-P5107A

Low molecular weight protamine acetate LMWP acetate; TDSP5 acetate	VEGFR	Cancer
Low molecular weight protamine acetate (LMWP acetate;TDSP5 acetate) is a truncated arginine-rich protamine peptide, which also acts as an antidote for heparin/low molecular weight heparin and a cell-penetrating delivery vector. Low molecular weight protamine acetate neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities. Low molecular weight protamine acetate translocates across mammalian cell membranes, delivers conjugated impermeable molecules through tumor tissues, enhances the skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine acetate retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine acetate can be used in studies related to colon cancer, skin wounds and diabetic skin wounds .

HY-P4576

Methoxycarbonyl-D-Nle-Gly-Arg-pNA	Factor Xa	Others
Methoxycarbonyl-D-Nle-Gly-Arg-pNA is a synthetic trypsin that can serve as a substrate for coagulation factors IXa (FIXa) and Xa (FXa) .

HY-P6023B

D-Leu-Pro-Arg-Rh110-D-Pro acetate	Factor Xa	Cardiovascular Disease
D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990060

Denecimig Mim8	Factor Xa	Cardiovascular Disease
Denecimig (Mim8) is a factor VIII-mimetic bispecific antibody with micromolar human binding affinity for Factor X and Factor IXa. Denecimig binds Factor X and Factor IXa, localizes both to the phospholipid surface, enhances the Factor IXa-mediated activation of Factor X to Factor Xa, and stimulates the proteolytic activity of Factor IXa via its monovalent anti-Factor IXa arm. Denecimig is applicable to research related to hemophilia A .

HY-P99326

Tositumomab Anti-Human CD20 Recombinant Antibody; V10Xa53	CD20	Cancer
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6987

Licraside	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	FXR Factor Xa
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-N2082

Isorhamnetin 3-O-galactoside 1 Publications Verification Cacticin	Cardiovascular Disease Flavonols Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification	Thrombin COX ERK JNK Factor Xa
Isorhamnetin 3-O-galactoside (Cacticin) is a flavonoid glycoside that can be isolated from Oenanthe javanica, with antithrombotic and profibrinolytic activities. Isorhamnetin 3-O-galactoside inhibits the activities of thrombin and factor Xa (FXa) and reduces thrombin-catalyzed fibrin polymerization maximum rate. Isorhamnetin 3-O-galactoside suppresses TNF-α-induced PAI-1 secretion, decreases the PAI-1/tissue-type plasminogen activator (t-PA) ratio, and inhibits FXa production and FVa/FXa-mediated thrombin generation. Isorhamnetin 3-O-galactoside exerts protective effects against Carbon tetrachloride (CCl4) (HY-Y0298)-induced hepatic injury in mice. Isorhamnetin 3-O-galactoside can be used for the study of liver injury-related diseases and thrombotic vascular diseases .

HY-N13950

Bacithrocin A	Natural Products Microorganisms Source Classification	Thrombin Factor Xa Ser/Thr Protease
Bacithrocin A is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 48 μM, 13 μM, 0.65 μM, and 0.02 μM, respectively .

HY-N13957

Bacithrocin C	Natural Products Microorganisms Source Classification	Thrombin Factor Xa Ser/Thr Protease
Bacithrocin C is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 80 μM, 15 μM, 1.3 μM, and 0.02 μM, respectively .

HY-N13955

Bacithrocin B	Natural Products Microorganisms Source Classification	Thrombin Factor Xa Ser/Thr Protease
Bacithrocin B is a thrombin inhibitor that inhibits thrombin, factor Xa, trypsin and Papain with IC₅₀s of 84 μM, 17 μM, 1.7 μM, and 0.02 μM, respectively .

HY-N13960

Bacithrocin D Thiolstatin D	Natural Products Microorganisms Ketones, Aldehydes, Acids Source Classification	Thrombin Factor Xa
Bacithrocin D (Thiolstatin D) inhibits multiple proteases and can prolong the clotting time. Bacithrocin D has IC₅₀ values of 124, 9, 0.85, and 0.01 μM for thrombin, factor Xa, trypsin, and papain, respectively .

HY-N7700B

L-Guluronic acid	Structural Classification Natural Products Microorganisms Source Classification	Factor Xa
L-Guluronic acid is a coagulation factor X inhibitor. L-Guluronic acid can replace L-Iduronic acid (HY-135197) in the anticoagulant pentasaccharide of heparin-like substances, while retaining the inhibitory activity against factor Xa. L-Guluronic acid can be used in the research of diseases with coagulation disorders such as deep vein thrombosis and pulmonary embolism .

Cat. No.	Product Name	Chemical Structure

HY-50903S

Rivaroxaban-d4 1 Publications Verification
Rivaroxaban-d₄ (BAY 59-7939-d₄) is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC₅₀ 0.7 nM; K_i 0.4 nM) .

HY-50667S

Apixaban-13C,d3
Apixaban- ¹³C,d₃ (BMS-562247-01- ¹³C,d₃) is a deuterium and ¹³C labeled Apixaban (HY-50667). Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-50667S1

Apixaban-d3
Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_is of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-10264S

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-10268S

Betrixaban-d6
Betrixaban-d₆ is a deuterium labeled Betrixaban. Betrixaban is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor .

HY-12605S

SAR107375-d11 Tartrate
SAR107375-d₁₁ (Tartrate) is deuterium labeled SAR107375. SAR107375 is a potent and orally active dual thrombin and factor Xa inhibitor, with K_i values of 1 nM and 8 nM for factor Xa and thrombin, respectively .

HY-10268S1

Betrixaban-d4
Betrixaban-d₄ (PRT054021-d₄) is deuterium labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-18660S

Ciraparantag-d8 (tetra(hydrochloride) diacetate)

Ciraparantag-d₈ (PER977-d₈) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .

HY-10268S2

Betrixaban-13C6
Betrixaban- ¹³C₆ (PRT054021- ¹³C₆) is ¹³C labeled Betrixaban. Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC₅₀ of 1.5 nM. Betrixaban shows antithrombotic effect .

HY-10280S

YM-60828-d3
YM-60828-d₃ is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81604

	Factor X Antibody (YA1349) Activated factor Xa heavy chain; Coagulation factor X; F10; factor Xa; FXa; Prothrombinase; Stuart factor	WB, IHC-P	Human
	Factor X Antibody (YA1349) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Factor X.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-153480A

ARC19499 sodium 1 Publications Verification BAX499 sodium		Aptamers
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480

ARC19499 BAX499		Aptamers
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks